Introduction
Trithorax (Trx) and polycomb (PcG) group proteins have crucial yet opposing roles in the regulation of key genes involved in development and stem cell maintenance. 1 The expression of these genes is tightly regulated during cell differentiation, with PcG complexes repressing and Trx promoting transcription. 2 PcG and Trx proteins regulate transcription by influencing chromatin structure, in part through covalent modification of histones. One group of genes regulated in this manner is HOX genes. 3 HOX gene expression is maintained at high levels in hematopoietic progenitors, and is coordinately decreased as these cells differentiate. 4 The Trx group protein MLL maintains HOX gene expression in hematopoietic progenitors, at least in part through trimethylation of histone H3 at lysine 4 (H3K4m3) via its C-terminal SET domain. 5 Chromosomal translocations involving the MLL gene result in the formation of MLL fusion proteins (MLL-FPs), which disrupt normal MLL function, causing acute leukemia. MLL translocated leukemias represent ~10% of adult acute leukemias and the majority of infant leukemia cases, and these patients have a poor prognosis. 6, 7 MLL-FPs promote the expression of a subset of wild-type (WT) MLL target genes, including
HOX genes, through recruitment of the histone H3K79 methyltransferase Dot1L and the pTEFb complex, enhancing transcriptional elongation. [8] [9] [10] [11] [12] MLL-FPs lack a large C-terminal portion of the WT MLL protein, including the histone H3 lysine 4 (H3K4)-methylating SET domain. This functional deficiency is remedied by expression of WT MLL from the non-translocated MLL allele. WT MLL works in concert with MLL-FPs to upregulate HOX genes and promote leukemia, highlighting a critical role for WT MLL in this disease. 13 
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WT MLL and MLL-FPs are recruited to target genes through binding to menin, which is encoded by the Men1 gene. [13] [14] [15] [16] X-ray crystallographic studies have recently shown that menin interacts with the identical N-terminal sequences of both WT MLL and MLL-FPs via a deep central pocket, demonstrating that menin is a close partner of these proteins. 17, 18 This interaction is required for leukemic transformation, highlighting a central role for menin in MLL-FP leukemia. 19 A major hallmark of leukemia and consequence of MLL-FP expression is a block in hematopoietic differentiation. 20 MLL-AF9 (MA9) leukemia cells have a block in the myeloid lineage at the granulocyte-macrophage progenitor stage, with cells expressing high levels of the cell surface receptor c-kit being enriched for leukemia-initiating cells (LICs). [21] [22] [23] [24] While HOX genes are at least partially responsible for this suppression of differentiation, it remains unclear how MLL-FP leukemia cells are blocked at the progenitor stage. 25, 26 In addition, global analysis has identified over 200 direct MLL-FP target genes, some of which could also have a role in blocking differentiation. 12 C/EBPα is a leucine zipper transcription factor that promotes myeloid differentiation in part through the activation of differentiation-associated genes. Many leukemogenic oncogenes and pathways inhibit the expression/function of C/EBPα as a means of blocking differentiation, including Bcr-Abl, AML-ETO, and Notch/Trib2. 27 However, little is known as to whether repression of C/EBPα is involved in blocking differentiation in MLL-FP leukemias. 28, 29 However, recent work has demonstrated that ectopic expression of EZH2 causes a block in myeloid differentiation, leading to the development of myeloproliferative disease. 30 Thus, the role of EZH2 in hematopoietic development and leukemia is not well understood. Utilizing murine models for MA9 leukemia, we set out to examine the role of the Trx protein MLL and its partner menin in regulating MA9 cell differentiation in vivo, and found that the polycomb protein EZH2 is a collaborating factor in suppressing C/EBPα and differentiation in MA9-induced leukemia.
Design and Methods

Plasmids and cell culture
The following plasmids were described elsewhere: pMIG-MLL-AF9-ires-GFP, pMSCVpgkHoxa9-GFP, pMSCVpac-Meis1A, and pcDNA3-CEBPA-HA. 16 
Recombinant retroviral and lentiviral packaging and cell transduction
Plasmids for retroviral packaging were co-transfected with psi-2 helper plasmid into 293T cells using the calcium chloride precipitation method. For lentiviral shRNA packaging, scrambled pLKO.1 vector or specific shRNA in pLKO.1 vector were co-transfected into 293T cells with pAX2G and pMD2G as previously described. 13 The resulting recombinant virus was collected for transduction of cells by spinoculation, followed by selection in 2 μg/ml puromycin for 3 days.
Murine transplantation experiments with Men1 or WT Mll excision
; Cre-ER mice (6-8 weeks old) were injected with 5-FU and sacrificed 5 days later for bone marrow isolation. Bone marrow was pre-stimulated with a mixture of cytokines as previously described. 16 Cells were then transduced with MLL-AF9-ires-GFP and Organs from mice were fixed, processed and H&E stained for microscopic analysis. A principal components analysis (PCA) was done to visually assess similarities and differences among the samples. For the identification of differentially expressed genes, we used the Cyber-T method. Multiple testing correction was applied using the p.adjust function. GSEA was performed to identify gene sets that were enriched in the microarray data. Gene sets were taken from the MSigDB database.
Chromatin immunoprecipitation (ChIP) assay, immunoprecipitation (IP), and antibodies
ChIP assays were performed as previously described using the Imgenex kit. 16 Briefly, 10 6 -10 7 formaldehyde crosslinked cells were lysed and sonicated to obtain sheared DNA. This lysate was then incubated with control IgG or an antigen-specific antibody overnight, then bound to beads and washed. Samples were eluted from the beads and incubated at 65°C overnight to 9 reverse crosslinking. Eluted DNA was quantified using the 7500 fast real-time PCR system (Applied Biosystems) with the Quantitect Sybr Green kit (Qiagen), and normalized to input DNA, as well as total H3 for histone modifications. Oligos used for ChIP real-time PCR are provided in the supplementary information.
RNA isolation and quantitative real-time PCR
RNA was isolated using Trizol (Ambion) and the RNeasy kit (Qiagen). 1μg of total RNA was used to make cDNA with the SS III RT system (invitrogen), and real-time PCR was performed using the 7500 fast real-time PCR system (Applied Biosystems) and Quantitect Sybr Green kit (Qiagen). Transcript levels were normalized to GAPDH between samples, and relative quantity was calculated using the ΔΔCt method.
Statistical analysis
GraphPad Prism was used for statistical analysis. Student's t-test was used for most statistical analysis of significance, except for the Kaplan-Meier analysis, which used the log-rank test.
Statistical analysis of microarray results is detailed above.
Results
Acute menin depletion causes MA9 cell differentiation in culture
To determine the effect of acute menin depletion on MA9 cell differentiation, we utilized the murine MA9 cell line AT-1, which contains floxed Men1 alleles and the Cre-ER transgene, allowing Men1 excision by addition of 4-hydroxytamoxifen (4-OHT) to the culture medium. 16 This increase in Gr-1 high cells also corresponded with a cell morphology change consistent with myeloid differentiation ( Figure 1D , right).
The ability to observe cell differentiation in this setting allowed us to next explore how menin depletion affects genes that regulate this process over time. The direct menin/MA9 target gene Hoxa9, which is at least partially responsible for the MA9-mediated differentiation block, 25, 26 was decreased as early as day 4 post 4-OHT treatment, prior to cell differentiation ( Figure 1E ). 
Acute menin depletion causes MA9 cell differentiation in vivo
To determine if menin depletion is pathologically relevant to MA9-induced leukemia, we Consistent with this increased Gr-1 high population, we observed mature differentiated myeloid cells in H&E-stained spleen sections from mice treated with TAM to deplete menin ( Figure 2C ).
In contrast to the immediate increase in the percentage of Gr-1 high cells, the c-kit high population, which is enriched for leukemia initiating cells (LICs), was unchanged at day 4 post-treatment, but decreased significantly by day 7 ( Figure 2E ). Further analysis of the relationship between ckit and Gr-1 revealed an increase in the c-kit high /Gr-1 high population at day 4 ( Figure S2A ), followed by a loss of this population at day 7 ( Figure S2B ). We also observed increased staining for the apoptotic marker Annexin V at day 7 ( Figure S2C ). These results suggest that as a consequence of menin depletion, c-kit high cells first gain expression of Gr-1, then either lose ckit expression during the process of differentiation or undergo cell death, leading to the depletion of c-kit high MA9 LICs.
WT MLL depletion causes MA9 cell differentiation in vivo
Due to the observed effect of menin depletion on MA9 cells, we hypothesized that acute depletion of WT MLL, which interacts with menin and is required to maintain MA9-mediated transformation, 13 Given that WT MLL depletion had a less pronounced increase in Gr-1 high MA9 cells than that of menin, we wondered whether Gr-1 low cells lacking WT MLL were defective in propagating leukemic disease. To address this question, we isolated control and WT Mll-excised MA9 splenocytes ( Figure S4A -B) from primary recipients, sorted into either Gr-1 low or Gr-1 high MA9
cell populations, and transplanted these cells into lethally irradiated secondary recipient mice.
WT MLL-depleted Gr-1 low recipients had a significantly longer survival rate than the WT MLLcontaining Gr-1 low cohort ( Figure S3F ), likely due to the decreased population of c-kit high cells in this group ( Figure S3E ). This survival effect may have been less pronounced due to the eventual 13 outgrowth of MA9 cells resistant to Mll excision in about half of the TAM-treated Gr-1 low recipients ( Figure S4C ). Consistent with previously published results, Gr-1 high recipient mice from each treatment group had significantly longer survival rates than their Gr-1 low counterparts ( Figure S3F ). 24 Together, these data demonstrate a role for WT MLL in maintaining a population of Gr-1 low /c-kit high MA9 cells, which possess the ability to propagate leukemic disease.
Menin depletion leads to the upregulation of C/EBPα target genes in MA9 cells in vivo
To investigate a potential mechanism for the menin/WT MLL-mediated block in myeloid differentiation, we performed a cDNA microarray using primary GFP + MA9 splenocytes from either control or Men1-excised recipient mice. We isolated cells at day 4 post-initial gavage to determine genes affected by menin depletion, and performed gene set enrichment analysis As multiple leukemogenic pathways affect the expression level of C/EBPα p42 or increase the ratio of the dominant negative p30 isoform over p42, 27 we first explored whether menin depletion affected C/EBPα expression or target gene binding in AT-1 cells. Although overexpression of C/EBPα-ER followed by activation via addition of 4-OHT to the culture medium was able to drive differentiation ( Figure 3B ), we failed to observe a menin-dependent effect on C/EBPα protein levels ( Figure 3C ). In addition, there was no detectable expression of 14 C/EBPα p30, which has been reported to promote leukemia development ( Figure 3C ). 32 Chromatin immunoprecipitation (ChIP) assay indicated that C/EBPα was able to bind the promoter of its target gene Mcsfr regardless of menin expression ( Figure 3D ). The lack of a direct effect on C/EBPα protein led us to investigate a potential role for menin in actively repressing C/EBPα target genes.
Menin promotes EZH2 expression in MA9 cells
In exploring potential repressors of C/EBPα function that may be regulated by menin/WT MLL, we observed that Mecom, which encodes the transcription factor Evi-1, was the most downregulated gene in response to acute menin depletion in vivo and was also decreased in Men1-excised AT-1 cells ( Figure 4A ). Evi-1 is directly activated by MA9, and is required for the maintenance of MLL-ENL transformed cells. 33 An Evi-1 oncogenic fusion protein has been
shown to repress C/EBPα at target genes, and Evi-1 has been reported to mediate transcriptional repression of the tumor suppressor PTEN through its interaction with PcG proteins, including EZH2.
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Surprisingly, we found that expression of EZH2, the catalytic component of polycomb repressive complex 2 (PRC2), was also decreased upon menin depletion in MA9-expressing cells ( Figure   4A -B), while expression of the closely related EZH1 was unaffected ( Figure S6B ). This effect on EZH2 occurs independent of Hoxa9/Meis1, as overexpression of these genes is unable to rescue the decrease in Ezh2 transcript levels due to menin depletion ( Figure S6A ). These findings suggest that in addition to Mecom, Ezh2 is a direct target of menin/MA9. Along these lines, ChIP assay showed enrichment for menin and the portion of AF9 found in MA9 (AF9c) at the Ezh2 and Mecom promoters. As expected, this enrichment was diminished by menin depletion ( Figure 4C ). ChIP using an MLL-C antibody, which specifically detects WT MLL, found that WT MLL also bound the Ezh2 promoter in a menin-dependent fashion ( Figure 4D ).
In addition, H3K4m3 and H3K79m2, which are associated with upregulation of gene transcription, 1, 37 were reduced at a certain part of the Ezh2 locus ( Figure 4E ). Together, these results demonstrate that menin promotes EZH2 expression, suggesting that menin/WT MLL/MA9 promote EZH2-mediated repression of C/EBPα target genes, leading to a block in MA9 leukemia cell differentiation.
EZH2 interacts with C/EBPα and represses its transcriptional activity
To test whether EZH2 inhibits C/EBPα function, we first determined whether EZH2 could repress C/EBPα-mediated transcriptional activation. To this end, we transfected 293T cells with a C/EBPα binding site-containing promoter-driven luciferase reporter, 31 C/EBPα, and increasing amounts of EZH2 expression plasmids. C/EBPα robustly activated the luciferase reporter, and EZH2 repressed C/EBPα-mediated activation in a dose-dependent manner ( Figure 5A ). As a control, EZH2 was unable to repress Gli1-activated luciferase ( Figure 5B ). EZH2 also repressed C/EBPα-activated luciferase in myeloid (RAW264.7) cells ( Figure 5C ). As EZH2 could repress C/EBPα-mediated activation, we decided to test the possibility that EZH2 physically interacts with C/EBPα in MA9 cells by performing immunoprecipitation (IP) experiments using endogenously expressed proteins in THP-1 cells. While it is unclear whether C/EBPα directly or indirectly binds EZH2, IP of C/EBPα was able to bring down EZH2 ( Figure 5D ), and IP of EZH2 pulled down C/EBPα ( Figure 5E ), showing that these proteins physically interact at endogenous levels in MA9 leukemia cells.
EZH2 binds C/EBPα target genes and suppresses MA9 cell differentiation
Since EZH2 interacts with C/EBPα in MA9 cells and represses its transcriptional activity, we reasoned that EZH2 could bind C/EBPα target genes to mediate direct repression. To explore this possibility, we performed ChIP to determine whether EZH2 bound to the promoter of C/EBPα target genes in AT-1 cells. ChIP assay showed that EZH2 binding was enriched at the 
Discussion
Depletion of the Trx protein MLL or its partner menin triggers MA9 cell differentiation
One of the major mechanisms for MA9-mediated leukemogenesis is causing a block in mature myeloid differentiation, 38 Figure 1F ). However, Hoxa9/Meis1 overexpression is able to compensate for defects in colony formation in methylcellulose due to menin depletion. 16 It is possible that in more stressed conditions, such as liquid culture, Hoxa9/Meis1 alone are unable to compensate for menin loss.
The acute effect of menin depletion in MA9 cells had a more drastic effect than that of WT MLL on differentiation and apoptosis. WT MLL KD in human MA9 cells causes decreased H3K79m2 at target genes, suggesting that WT MLL is required for MA9 recruitment. 13 Additionally, in MLL-null MEF cells, MA9 is unable to bind the Hoxa9 promoter. 42 However, there is no physical interaction between WT MLL and MA9, suggesting that MA9 recruitment resulting from WT MLL function at target gene promoters is an indirect process. In contrast, menin directly binds both WT MLL and MA9 via their common N-terminal domains and is required for their recruitment to target genes. The acute effect of menin loss could be more drastic than WT MLL loss alone, because menin is directly responsible for the recruitment of both WT MLL and MA9 to target genes to enhance their transcription.
Menin promotes EZH2 transcription in MA9 leukemia cells
Little has been known about the role of Trx complex components menin and MLL in regulating the expression of their rival polycomb genes. We have observed a substantial reduction in EZH2 expression following Men1 excision ( Figure 4A-B) . Menin, AF9c, and WT MLL bind the Ezh2 promoter, and their binding is decreased in response to menin loss ( Figure 4C-D) , suggesting that menin recruits MA9 and WT MLL to the Ezh2 promoter to upregulate EZH2 expression. It is not yet clear whether menin regulates the expression of EZH2 in other leukemias or normal hematopoietic cells, or why menin might promote the expression of protein complexes that oppose its function at common target genes. One possibility is that during development or in stem/progenitor cells, menin/MLL promote the expression of PRC components to preserve "bivalent" histone methylation, with both H3K4m3 and H3K27m3 at relevant promoters, leaving these genes repressed, but poised for activation. 2 The maintenance of bivalency is critical for the regulated expression of these genes, and may be the rationale behind menin/MLL-mediated activation of PRC protein expression in a developmental context.
EZH2 represses C/EBPα target genes in MA9 leukemia cells
C/EBPα is a critical transcription factor that controls myeloid differentiation, 43 and its normal function is inhibited through mutation, aberrant expression, or oncogene-mediated suppression, contributing to a block in myeloid differentiation in various leukemias. 43, 44 Little has been known about whether and/or how C/EBPα is regulated in MA9 leukemia cells. Consistent with our findings, recent reports show that EZH2 depletion causes primary leukemia cell differentiation. [46] [47] [48] However, EZH2 knockout seems to have a less severe effect on MA9 cells in vivo. 46 One potential reason for this more mild effect is partial compensation for loss of EZH2 function by the closely related EZH1 protein, which can also be found in the PRC2 complex and catalyzes H3K27 methylation. In fact, depletion of the core PRC2 component EED, which is essential for both EZH1 and EZH2 function, more effectively extends the life span of MA9 leukemic mice than EZH2 knockout. 46 In addition, combined knockdown of EZH1 and EZH2 more effectively reduces MA9 cell growth than EZH2 knockdown alone 47 , providing further evidence that EZH1 can at least partially compensate for EZH2 loss under certain conditions.
The role of EZH2 in regulating C/EBPα function during normal hematopoiesis and in other leukemia types remains to be examined. Although EZH2 is required for stem/progenitor cell expansion in developmental hematopoiesis, EZH2 depletion in adult BM is less severe, with no effect on LSK cells, but impaired differentiation of lymphoid cells, and increased myeloerythroid progenitors, suggesting that EZH2 does regulate at least some stages of myeloid differentiation. 49 Future studies will clarify whether EZH2 specifically regulates C/EBPα function in MA9 cells or in a broader spectrum of cell types.
A context-dependent role for EZH2 in hematopoietic malignancies
The role of EZH2 in hematopoietic malignancies is complex, and seems to be context dependent.
In myelodysplastic/ myeloproliferative disorders, mono-or bi-allelic mutations were found in 12% of patients, suggesting EZH2 may be a tumor suppressor in the myeloid lineage 28, 29 .
However, in lymphomas of germinal center origin, a specific recurring point mutation in the SET domain of EZH2, converting tyrosine 646 to cytosine has been observed. 50, 51 This mutation causes increased H3K27 methyltransferase activity, suggesting that EZH2 function promotes tumorigenesis in this disease. 52, 53 EZH2 is involved in suppressing PTEN expression and promoting AKT signaling in Evi-1-induced leukemia cells, 36 yet we found that EZH2 knockdown did not affect PTEN expression in MA9 leukemia cells, suggesting an alternative mechanism for EZH2 in regulating MA9 cell differentiation.
Consistent with the role of EZH2 in regulating differentiation, EZH2 has been reported to promote MA9 leukemias. 46, 47 It has been unclear as to how mature differentiation of MA9-induced leukemia is blocked. We found for the first time that in MA9-induced leukemia, menin plays a key role in promoting the expression of the polycomb protein EZH2. EZH2 cooperates with menin to epigenetically suppress the expression of pro-differentiation C/EBPα targets and block the mature differentiation of MA9 leukemia cells ( Figure 6F ). These findings unravel a novel mechanism for EZH2 in blocking MLL-AF9 leukemia cell differentiation.
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Supplemental Material
Antibodies
The following antibodies were used for flow cytometry: Anti-mouse Gr-1 (Ly6c/Ly6g) (Cat #557979, BD or Cat #108412, BD), Annexin V (Cat #550474, BD), anti-mouse CD117 (c-kit) (Cat #47-1171-80, eBioscience), anti-mouse CD11b (Cat #101228, Biolegend or Cat # 553311, BD), and anti-human CD11b (Cat #561001, BD).
The following antibodies were used for IP/ChIP/Western blots: EZH2 (Cat#612666, BD or Cat#17-662, Millipore), C/EBPα (Cat#2295, Cell Signaling or Cat# SC-61, Santa Cruz), IgG (Abcam Cat#ab46540), Evi-1 (Cat #C50E12 Cell Signaling), Menin (Cat#A300-105A, Bethyl), MLL-C (Cat#ABE240, Millipore) AF9c (Cat#A300-597A, Bethyl), H3K4m3 (Cat #ab8580, Abcam), H3K79m2 (Cat #ab3594, Abcam), H3K27m3 (Cat #17-622 Millipore), and total H3 (Cat #ab1791, Abcam).
Real-Time PCR Oligos
Mouse: 
